ProPublica reports on FDA exemptions allowing banned foreign factories to ship drugs to the U.S., raising concerns about drug quality, patient safety, and regulatory oversight. Focus on FDA and sunlight pharma.
FDA staff cuts impacting crucial international drug factory inspections, potentially jeopardizing the safety of medications used by millions. ProPublica reveals safety concerns and staff depletion.
ProPublica reveals FDA's loophole allowing over 150 drugs from banned factories with mold/filth to enter the US, raising safety concerns and potential patient harm.
